Inhibition of Rat Ovarian 3Β-Hydroxysteroid Dehydrogenase

Total Page:16

File Type:pdf, Size:1020Kb

Inhibition of Rat Ovarian 3Β-Hydroxysteroid Dehydrogenase Endocrinol. Japon. 1989, 36 (3), 387-394 Inhibition of Rat Ovarian 3ƒÀ-Hydroxysteroid Dehydrogenase (3ƒÀ-HSD), 17ƒ¿-Hydroxylase and 17,20 Lyase by Progestins and Danazol SATOKO ARAKAWA, MIZUE MITSUMA, MASATO IYO, RYOICHI OHKAWA, AKIRA KAMBEGAWA, SHoicm OKINAGA AND KIYOSHI ARAI Department of Obstetrics and Gynecology, Teikyo University School of Medicine 2-11-1 Kaga Itabashi-ku, Tokyo, Japan Abstract The site of action of synthetic progestins or danazol in the treatment of endometriosis is considered to be mainly the hypothalamo-pituitary level, but the direct action to the uterine endometrium and the ovary is also suggested. We investigated the effect of these synthetic steroids to rat ovarian steroido- genic enzymes. The effect of norethisterone, levonorgestrel, danazol, gestri- none, desogestrel and 3-keto-desogestrel was studied in vitro. The sources of the enzymes were prepared from ovaries of immature rats treated either with pregnant mare serum gonadotropin (PMS) and human chorionic gonadotropin (hCG) for 3ƒÀ-hydroxy steroid dehydrogenase (3ƒÀ-HSD), or with PMS for 17ƒ¿- hydroxylase and 17,20 lyase. The substrates used were pregnenolone (P5) for 3ƒÀ-HSD, progesterone (P4) for 17ƒ¿-hydroxylase, and 17ƒ¿-hydroxy-progesterone (17ƒ¿-OH-P4) for 17,20 lyase. The substrates were incubated with the enzyme sources and coenzymes, and the products formed were measured. All the steroids inhibited 3ƒÀ-HSD, and the inhibition by gestrinone (Ki= 3.0ƒÊM) and 3-keto-desogestrel (17.5ƒÊM) was particularly marked. Only desogestrel (Ki= 30.3ƒÊM) and danazol (168ƒÊM) inhibited 17ƒ¿-hydroxylase. All the steroids inhibited 17,20 lyase, and the inhibition by desogestrel (Ki= 0.70ƒÊM), danazol (0.80ƒÊM), and gestrinone (30ƒÊM) was particularly marked. The site of action of synthetic progestins and danazol (Barbieri et al.; 1977, Barbieri and danazol in the treatment of endo- et al.; 1981) inhibit ovarian enzymes di- metriosis is considered to be mainly the rectly. In the following study, we investi- hypothalamo-pituitary level (Franchimont gated the effect of synthetic steroids on rat and Cramilion, 1977; Franchimont et al., ovarian 3ƒÀ-hydroxy steroid dehydrogenase 1970; McDonald and Gilmore, 1971; (3ƒÀ-HSD), 17ƒ¿-hydroxylase, and 17,20 Cullberg et al., 1982; Garmendia et al., lyase. 1976). But the direct effect of synthetic steroids on ovarian enzymes was also re- ported. Norethisterone (Shinada et al., Materials and Methods 1978;Johansson, 1971), levonorgestrel (Mukherjee et al.; 1972, Johansson; 1971) Chemical Received January 20, 1989 [4-14C]-pregnenolone (P5) (57.2 mCi/mmol), Endocrinol. Japon. 388 ARAKAWA et al. June 1989 [4-14C]-progesterone (P4) (57.2 mCi/mmol),[4-14C]- hibitor. For assays of 17ƒ¿-hydroxylase and 17ƒ¿-hydroxy progesterone (17ƒ¿-OH-P4) (50 mCi/ 17,20 lyase, each incubation mixture (1ml) con- mmol), [1, 2, 6, 7-3H(N)]-P4 (106.8 Ci/mmol) and tained a preparation of tissue from PMS treated 17ƒ¿-[1, 2-3H(N)] hydroxy P4 (57.4 Ci/mmol) were rats (12-15ƒÊg protein), 0.5ƒÊmol of NADPH, 14C- or 3H-steroid (about 0 purchased from New England Nuclear Corp. .03ƒÊCi, 0.1-4 mol) (Boston, MA, USA). NAD and NADPH were and an inhibitor. Labelled P4 was employed the products of Boehringer (Mannheim, Ger- for a 17ƒ¿-hydroxylase assay, and labelled 17ƒ¿- many). Norethisterone, levonorgestrel, pregnant OH-P4 for a 17, 20 lyase assay. The mixture mare serum gonadotropin (PMS) and human was incubated in a Dubnoff-type incubator at chorionic gonadotropin (hCG) were provided 37•Ž for various time intervals. The incubation by Teikoku Hormone Co.(Japan, Tokyo). was terminated by chilling in an ice bath. Desogestrel and 3-keto-desogestrel were a gift Steroids were extracted with ether (5ml). A from Organon Co.(Holland). Danazol was mixture of nonradioactive carrier steroids was provided by Tokyo Tanabe (Japan), and gestri- added to each extract, which was then applied none by Roussel Uclaf (Paris, France). All to a silica gel thin layer plate and developed chemicals and reagents used were of analytical in a solvent system of benzene-acetone (4:1, grade. v/v). Steroids which were not separable in this system were sub jected to further thin layer Preparation of enzymes chromatography in the following solvent system: Immature female rats of the Wistar-Imamichi cyclohexane-ethyl acetate (1:1, v/v) was employ- strain were used. Ten IU of PMS was injected ed for the separations of androstenedione from subcutaneously (s. c.) at 9:00 h, on the 23rd day 3ƒ¿-hydroxy-5ƒ¿-pregnan-20-one and of 17ƒ¿-OH- of life. PMS treated rats were decapitated at P4 from 3ƒÀ-hydroxy-5ƒ¿-pregnan-20-one. Andro- 17:00 h two days later. Another group of rats stenedione and 17ƒ¿-hydroxy-5ƒ¿-pregnane-3,20- were given an injection of 30 IU of hCG at dione were completely separated by developing 14:00 h two days after PMS injection, and killed the plate three times in ethyl acetate-n-heptane three hours after the last treatment. Ovaries (2:5, v/v). Spots of the carrier on thin layer were homogenized in a teflon glass homogenizer chromatograms were located under an UV light with 0.25 M sucrose/0.05 M Tris HC1 buffer and (254 nm) or by being exposed to iodine vapor. then centrifuged at •~ 800 g for 20 min. The The 14C-spots were detected by autoradiography. supernatant was used as enzyme sources. Pro- Each spot was scraped off the plate, added with tein in the supernatant was determined by the 0.1ml methanol and 3ml toluene scintillator, Bradford's method (Bradford, 1976). and the radio-activity was measured in a liquid scintillation spectrometer (Aloka LSC 703). The Enzyme assay recovery of steroids was 55-70%. For an assay of 3ƒÀ-HSD, each incubation The enzyme activity was expressed as the mixture (1ml) contained a preparation of tissue sum of metabolites formed from radioactive from PMS-hCG treated rats (2.5-100ƒÊl of the substrates. Some of the results were analyzed enzyme; 1.5-61.1ƒÊg protein), 0.5ƒÊmol of NAD, by the method of Lineweaver-Burk (Lineweaver 14C-P5 (about 0 .03ƒÊCi, 1-100 nmol), and an in- and Burk, 1934). Table 1. Title;Identification of radioactive metabolites formed by repeated recrystallizations to constant specific radioactivities. Regend; Methanol-chloroform or methanol-water were used as the recrystallization solvent. Vol. 36, No. 3 INHIBITION OF OVARIAN ENZYME 389 Fig. 1a Statistical Analysis Statistical analysis of the results was done by Student's t-test, and a P value of less than 0.05 was considered significant. Results Autoradiography 3ƒÀ-HSD: A metabolite formed from P5 was only P4 under the experimental condi- tions used and the 3ƒÀ-HSD activity was expressed by the amount of P4 17ƒ¿-hy- droxylase: Metabolites formed from P4 were Fig. 1b 17ƒ¿-OH-P4, androstenedione and a small amount of other steroids. The 17ƒ¿-hy- droxylase activity was expressed as the sum of 17ƒ¿-OH-P4 and androstenedione formed. 17, 20 lyase: Metabolites from 17ƒ¿-OH-P4 were androstenedione and a small amount of other steroids. The 17, 20 lyase activity was expressed by the amount of andros- tenedione. These metabolites were crystallized re- peatedly with the corresponding standard steroids. Constant specific radioactivity of the crystals is shown in Table 1. Effect of incubation time and volume of the tissue preparation Fig. 1c Fig. la shows the relation between the product (P4) formed and the amount of enzyme in the 3ƒÀ-HSD assay. The con- centration of the substrate was 10ƒÊM, and the incubation time was 20 min. Fig. 1b and c show the relation between the amount of products formed and the incubation time in 17ƒ¿-hydroxylase and 17, 20 lyase. The concentration of the substrate was 1ƒÊM and the amount of the enzyme was 25ƒÊl (16.2ƒÊg protein). A subsequent study was performed in which the enzymatic reaction was not saturated. For the experiment on 3ƒÀ-HSD, 25ƒÊl of the enzyme (15.3ƒÊg Fig. 1. Title; Effects of the amount of the tissue preparation used for a) 3ƒÀ-HSD protein) was incubated for 20 min. For assay and of incubation time for b) 17ƒ¿- 17ƒ¿-hydroxylase, 25ƒÊl of the enzyme was hydroxylase and c) 17, 20 lyase. incubated for 10 min. For 17, 20 lyase, the Endocrinol. Japon. 390 ARAKAWA et al. June 1989 *P<0 .05 Fig.2 c **P<0. 01 ***P<0 .001 *P<0 .05 Fig.2 b **P<0 .01 *P<0 .05 Fig .2 a Fig. 2. Title; Inhibition of a) 3ƒÀ-HSD, b) 17 ƒ¿-hydroxylase and c) 17,20 lyase by various steroids. Regend; Vertical bars indicate mean•}standard error. 391 Vol.36, No.3 INHIBITION OF OVARIAN ENZYME Fig. 3a Fig. 3c LEVONORGESTREL PROGESIERONE NORETHISTERONE NOFIETHISTERONE 100μM 20μM 20μM 100μM LEVONORGESTREL DESOGESTREL 3KETO-DESOGESTREL 20μM 20μM DESOGESTREL 100μM 2μM GESTRINONE 3KETO-DESOGESTREL 2μM 20μM DANAZOL GESTPINONE 2μM 100μM DANAZOL 20μM Fig. 3. Title; Lineweaver Burk's plot in the inhibition study of a) 3ƒÀ-HSD, b) 17ƒ¿-hydroxylase and c) 17,20 lyase by various steroids. 3b DESOGESTREL DANAZOL ficantly when the concentration was 20μM enzyme volume was 20 or 25ƒÊl and the incubation time was 16 or 20min. (Fig. 2b). Most of the steroids inhibited 17,20 lyase significantly (Fig. 2c). Inhibition of enzymes by steroids Fig. 3 shows Lineweaver Burk's plot Fig. 2a shows the effect of various indicating the inhibitory effects of steroids steroids on 3ƒÀ-HSD activity. All steroids on enzymes. Table 2 summarizes the inhibited 3ƒÀ-HSD significantly when 20ƒÊM results of the kinetic studies on steroida- was used. However, no steroid, except genic enzymes. The inhibition of 3ƒÀ-HSD desogestrel, inhibited 17ƒ¿-hydroxylase signi- by gestrinone (Ki = 3.0ƒÊM) and 3-keto- Endocrinol.
Recommended publications
  • Package Leaflet: Information for the Patient Desogestrel Rowex
    Package leaflet: Information for the patient Desogestrel Rowex 75 microgram Film-coated tablets desogestrel Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Desogestrel Rowex is and what it is used for 2. What you need to know before you take Desogestrel Rowex 4. Possible side effects 5. How to store Desogestrel Rowex 6. Contents of the pack and other information 1. What Desogestrel Rowex is and what it is used for Desogestrel Rowex used to prevent pregnancy. There are 2 main kinds of hormone contraceptive. - The combined pill, "The Pill", which contains 2 types of female sex hormone an oestrogen and a progestogen, - The progestogen-only pill, POP, which doesn't contain an oestrogen. Desogestrel Rowex is a progestogen-only-pill (POP). Desogestrel Rowex contains a small amount of one type of female sex hormone, the progestogen desogestrel. Most POPs work primarily by preventing the sperm cells from entering the womb but do not always prevent the egg cell from ripening, which is the main way that combined pills work.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]
  • Desogestrel-Only Pill (Cerazette)
    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
    [Show full text]
  • Connecticut Medicaid
    ACNE AGENTS, TOPICAL ‡ ANGIOTENSIN MODULATOR COMBINATIONS ANTICONVULSANTS, CONT. CONNECTICUT MEDICAID (STEP THERAPY CATEGORY) AMLODIPINE / BENAZEPRIL (ORAL) LAMOTRIGINE CHEW DISPERS TAB (not ODT) (ORAL) (DX CODE REQUIRED - DIFFERIN, EPIDUO and RETIN-A) AMLODIPINE / OLMESARTAN (ORAL) LAMOTRIGINE TABLET (IR) (not ER) (ORAL) Preferred Drug List (PDL) ACNE MEDICATION LOTION (BENZOYL PEROXIDE) (TOPICAL)AMLODIPINE / VALSARTAN (ORAL) LEVETIRACETAM SOLUTION, IR TABLET (not ER) (ORAL) • The Connecticut Medicaid Preferred Drug List (PDL) is a BENZOYL PEROXIDE CREAM, WASH (not FOAM) (TOPICAL) OXCARBAZEPINE TABLET (ORAL) listing of prescription products selected by the BENZOYL PEROXIDE 5% and 10% GEL (OTC) (TOPICAL) ANTHELMINTICS PHENOBARBITAL ELIXIR, TABLET (ORAL) Pharmaceutical and Therapeutics Committee as efficacious, BENZOYL PEROXIDE 6% CLEANSER (OTC) (TOPICAL) ALBENDAZOLE TABLET (ORAL) PHENYTOIN CHEW TABLET, SUSPENSION (ORAL) safe and cost effective choices when prescribing for HUSKY CLINDAMYCIN PH 1% PLEGET (TOPICAL) BILTRICIDE TABLET (ORAL) PHENYTOIN SOD EXT CAPSULE (ORAL) A, HUSKY C, HUSKY D, Tuberculosis (TB) and Family CLINDAMYCIN PH 1% SOLUTION (not GEL or LOTION) (TOPICAL)IVERMECTIN TABLET (ORAL) PRIMIDONE (ORAL) Planning (FAMPL) clients. CLINDAMYCIN / BENZOYL PEROXIDE 1.2%-5% (DUAC) (TOPICAL) SABRIL 500 MG POWDER PACK (ORAL) • Preferred or Non-preferred status only applies to DIFFERIN 0.1% CREAM (TOPICAL) (not OTC GEL) (DX CODE REQ.) ANTI-ALLERGENS, ORAL SABRIL TABLET (ORAL) those medications that fall within the drug classes DIFFERIN
    [Show full text]
  • Coordinating Investigator
    Public Disclosure Synopsis Page 1 of 6 KF4248/05 12 July 2016 Confidential TITLE OF TRIAL: Safety of the oral monophasic contraceptive GRT4248 (0.02 mg ethinylestradiol/2 mg chlormadinone acetate) in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 6 medication cycles SPONSOR/COMPANY: Grünenthal GmbH, 52099 Aachen, Germany COORDINATING Milano, Italy INVESTIGATOR: TRIAL CENTER(S): Thirty-three centers in total: 11 in Germany, 4 in Spain, 5 in France, 6 in Italy, 2 in Portugal, 5 in Russia PUBLICATION Not applicable (REFERENCE): TRIAL PERIOD (YEARS): First subject enrolled: 08 NOV 2005 Last subject completed: 16 AUG 2006 Data-base lock 24 OCT 2006 PHASE OF DEVELOPMENT: Phase III OBJECTIVES: To determine the safety of 0.02 mg ethinylestradiol/2 mg chlormadinone acetate, given for 24 days each 28-day cycle in comparison to 0.02 mg ethinylestradiol/0.15 mg desogestrel given for 21 days each 28-day cycle. Each investigational medicinal product (IMP) was to be taken for 6 cycles. METHODOLOGY: Randomized, multicenter, double-blind, desogestrel-controlled, parallel group, multiple administration, Phase III trial NUMBER OF SUBJECTS: Subjects were allocated by randomization to two medication groups, one receiving 0.02 mg ethinylestradiol/2 mg chlormadinone acetate (the GRT4248 group) and one receiving 0.02 mg ethinylestradiol/0.15 mg desogestrel (the EE/DSG group). The planned and actual sizes of the two groups were: Grünenthal Public Disclosure Synopsis Page 2 of 6 Confidential KF4248/05 12 July 2016 Evaluated Medication Randomized
    [Show full text]
  • Guidance on Bioequivalence Studies for Reproductive Health Medicines
    Medicines Guidance Document 23 October 2019 Guidance on Bioequivalence Studies for Reproductive Health Medicines CONTENTS 1. Introduction........................................................................................................................................................... 2 2. Which products require a bioequivalence study? ................................................................................................ 3 3. Design and conduct of bioequivalence studies .................................................................................................... 4 3.1 Basic principles in the demonstration of bioequivalence ............................................................................... 4 3.2 Good clinical practice ..................................................................................................................................... 4 3.3 Contract research organizations .................................................................................................................... 5 3.4 Study design .................................................................................................................................................. 5 3.5 Comparator product ....................................................................................................................................... 6 3.6 Generic product .............................................................................................................................................. 6 3.7 Study subjects
    [Show full text]
  • The Effects of Hormonal Contraception on the Voice: History of Its Evolution in the Literature
    CARE OF THE PROFESSIONAL VOICE Robert T. Sataloff, Associate Editor The Effects of Hormonal Contraception on the Voice: History of its Evolution in the Literature Jennifer Rodney and Robert T. Sataloff [Modified from J. Rodney and R.T. Sataloff, “The Effects of Hormonal Contraception on the Voice: History of its Evolution in the Literature,” Journal of Voice 30, no. 6 (November 2016): 726–730; with permission.] INTRODUCTION: THE MENSTRUAL CYCLE AND THE VOICE The fluctuation of hormones in the menstrual cycle has significant effects on the voice.1 Singing teachers should be familiar with the vocal effects of Jennifer Rodney hormones and of hormonal medications such as oral contraceptives (birth control pills), especially in light of recent changes in their chemistry and effects. Vocal symptoms, known as dysphonia premenstrualis, accompany the better known symptoms of premenstrual syndrome (PMS) during the luteal phase of the menstrual cycle.2 The most common symptoms of dys- phonia premenstrualis are difficulty singing high notes, decreased flexibil- ity, huskiness, fuzziness, breathiness, decreased volume, difficulty bridging passaggios and intonation problems.3 Davis and Davis concluded that, on average, singers experience 33 general symptoms of PMS and 3 symptoms of dysphonia premenstrualis.4 Chae et al. showed that approximately 57% participants met the DSM IV criteria for PMS and also had acoustic evidence Robert T. Sataloff of dysphonia premenstrualis, whereas the PMS-negative group did not.5 The risk of vocal stress and possible damage during the premenstrual period led many European opera houses to offer singers contracts that included “grace days” during their premenstrual period. This accommodation is no longer followed in Europe and was never practiced generally in the United States.6 The mechanisms that cause these symptoms lie not just in the actions of the hormones themselves, but also in the cyclic fluctuation of hormone levels.
    [Show full text]
  • Combined Oral Contraceptives Plus Spironolactone Compared With
    177:5 M Alpañés, F Álvarez-Blasco Randomized trial of common 177:5 399–408 Clinical Study and others drugs for PCOS Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial Macarena Alpañés*, Francisco Álvarez-Blasco*, Elena Fernández-Durán, Manuel Luque-Ramírez and Héctor F Escobar-Morreale Correspondence Diabetes, Obesity and Human Reproduction Research Group, Department of Endocrinology & Nutrition, Hospital should be addressed Universitario Ramón y Cajal & Universidad de Alcalá & Instituto Ramón y Cajal de Investigación Sanitaria IRYCIS & to H F Escobar-Morreale Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas CIBERDEM, Madrid, Spain Email *(M Alpañés and F Álvarez-Blasco contributed equally to this work) hectorfrancisco.escobar@ salud.madrid.org Abstract Objective: We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS). Design: We conducted a randomized, parallel, open-label, clinical trial comparing COC (30 μg of ethinylestradiol and 150 μg of desogestrel) plus spironolactone (100 mg/day) with metformin (850 mg b.i.d.) for one year in women with PCOS (EudraCT2008–004531–38). Methods: The composite primary outcome included efficacy (amelioration of hirsutism, androgen excess and menstrual dysfunction) and cardiometabolic safety (changes in the frequencies of disorders of glucose tolerance, dyslipidemia and hypertension). A complete anthropometric, biochemical, hormonal and metabolic evaluation was conducted every three months and data were submitted to intention-to-treat analyses. European Journal European of Endocrinology Results: Twenty-four patients were assigned to COC plus spironolactone and 22 patients to metformin.
    [Show full text]
  • Makale16.Pdf
    Expert Opinion on Drug Metabolism & Toxicology ISSN: 1742-5255 (Print) 1744-7607 (Online) Journal homepage: http://www.tandfonline.com/loi/iemt20 Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis Fabio Barra, Carolina Scala & Simone Ferrero To cite this article: Fabio Barra, Carolina Scala & Simone Ferrero (2018): Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis, Expert Opinion on Drug Metabolism & Toxicology, DOI: 10.1080/17425255.2018.1461840 To link to this article: https://doi.org/10.1080/17425255.2018.1461840 Accepted author version posted online: 04 Apr 2018. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=iemt20 Publisher: Taylor & Francis Journal: Expert Opinion on Drug Metabolism & Toxicology DOI: 10.1080/17425255.2018.1461840 Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis Fabio Barra 1,2, Carolina Scala 1,2, Simone Ferrero 1,2 Institutions: 1 Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy 2 Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy Corresponding Author: Simone Ferrero MD, PhD; Academic Unit of Obstetrics and Gynecology, IRCCS AOU San Martino – IST, Largo R. Benzi 10, 16132 Genoa, Italy Telephone 01139 010 511525 Mobile 01139 3477211682 Fax 01139 010511525 E-mail: [email protected] Funding This paper was not funded. Declaration of interest: The authors have no relevant affiliations or financial involvement with any organization or entity with a financialAccepted interest in or financial conflict wi thManuscript the subject matter or materials discussed in the manuscript.
    [Show full text]
  • Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands
    Molecular and Preclinical Pharmacology of Nonsteroidal Androgen Receptor Ligands Dissertation Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Amanda Jones, M.S. Graduate Program in Pharmacy The Ohio State University 2010 Dissertation Committee: James T. Dalton, Advisor Thomas D. Schmittgen William L. Hayton Robert W. Brueggemeier Copyright by Amanda Jones 2010 Abstract The androgen receptor (AR) is critical for the growth and development of secondary sexual organs, muscle, bone and other tissues, making it an excellent therapeutic target. Ubiquitous expression of AR impedes the ability of endogenous steroids to function tissue selectively. In addition to the lack of tissue selectivity, clinical use of testosterone is limited due to poor bioavailability and pharmacokinetic problems. Our lab, in the last decade, discovered and developed tissue selective AR modulators (SARMs) that spare androgenic effects in secondary sexual organs, but demonstrate potential to treat muscle wasting diseases. This work reveals the discovery of next generation SARMs to treat prostate cancer and mechanistically characterize a prospective SARM in muscle and central nervous system (CNS). Prostate cancer relies on the AR for its growth, making it the primary therapeutic target in this disease. However, prolonged inhibition, with commercially available AR antagonists, leads to the development of mutations in its ligand binding domain resulting in resistance. Utilizing the crystal structure of AR-wild-type and AR-W741L mutant, we synthesized a series of AR pan- antagonists (that inhibit both wild-type and mutant ARs). Structure activity relationship studies indicate that sulfonyl and amine linkages of the aryl propionamide pharmacophore are important for the antagonist activity.
    [Show full text]
  • Effects of Dienogest, a Synthetic Steroid, on Experimental Endometriosis in Rats
    European Journal of Endocrinology (1998) 138 216–226 ISSN 0804-4643 Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats Yukio Katsuki, Yukiko Takano, Yoshihiro Futamura, Yasunori Shibutani, Daisuke Aoki1, Yasuhiro Udagawa1 and Shiro Nozawa1 Toxicology Laboratory, Mochida Pharmaceutical Co. Ltd, Fujieda, Shizuoka 426, Japan and 1Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo 160, Japan (Correspondence should be addressed to Y Katsuki, Toxicology Laboratory, Mochida Pharmaceutical Co. Ltd, 342 Gensuke Fujieda, Shizuoka 426, Japan) Abstract Objective: Dienogest, a synthetic steroid with progestational activity, is used as a component of oral contraceptives and is currently being evaluated clinically for the treatment of endometriosis. The present study was conducted to confirm the effects of dienogest on experimental endometriosis in rats and to elucidate its mechanism of action. Design: Experimental endometriosis induced by autotransplantation of endometrium in rats. Methods: Endometrial implants, immune system, and bone mineral were investigated after 3 weeks of medication. Results: Dienogest (0.1–1 mg/kg per day, p.o.) reduced the endometrial implant volume to the same extent as danazol (100 mg/kg per day, p.o.). Simultaneously, dienogest ameliorated the endometrial implant-induced alterations of the immune system; i.e. it increased the natural killer activity of peritoneal fluid cells and splenic cells, decreased the number of peritoneal fluid cells, and decreased interleukin-1b production by peritoneal macrophages. In contrast, danazol (100 mg/kg per day, p.o.) and buserelin (30 mg/kg per day, s.c.) had none of these immunologic effects. Additionally, combined administration of dienogest (0.1 mg/kg per day) plus buserelin (0.3 mg/kg per day) suppressed the bone mineral loss induced by buserelin alone, with no reduction of the effect on endometrial implants.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]